CD274 and neoplasm: The identification of biomarkers including mutational/neoantigen load [9] and the PDL1 expression on tumor and immune cells [10] might predict the responders who would benefit from this therapy, but, in most of the studies, these markers did not show any correlation with the anti-PD1 response [11].